News & Media

Conditions are ripe for transforming the U.S. mental health care system, with scientific advances, the growth of Medicaid, and political consensus on the importance of improving mental health creating the possibility that goals once thought out of reach may be possible, according to a new RAND Corporation study.

PRINCETON, N.J. and NEW YORK, N.Y. (November 24, 2020) – Otsuka Pharmaceutical Development & Commercialization, Inc., announced an agreement with research experts from the Columbia University Irving Center Vagelos College of Physicians and Surgeons and Mailman School of Public Health  to help support the epidemiological needs of Otsuka Global Pharmacovigilance (GPV) for products, enhanced

Activities will support the clinical development of Rugen’s potential first-in-class, orally administered drug candidate with initial clinical focus on treatment-resistant depression. PRINCETON, N.J. (October 30, 2020) – The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announced today that it has entered

Princeton, NEW JERSEY (October 21, 2020) – The Sozosei Foundation, a new philanthropy, has been launched to address the over-incarceration of people with mental illness and is convening an inaugural summit December 14-16 on this topic. Sozosei will also lead corporate social responsibility activities focused on disaster relief and local philanthropy, which will be centered on equity and